Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Reduce" from Brokerages

Key Points

• Y-mAbs Therapeutics has received a consensus recommendation of "Reduce" from ten research firms, with two analysts issuing a sell recommendation and eight a hold recommendation.
• The average 12-month price target for Y-mAbs Therapeutics is $9.62, following recent downgrades from several brokerage firms.
• Despite a negative return on equity of 24.60%, the company reported revenue of $19.52 million for the last quarter, surpassing consensus estimates.

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have been assigned a consensus recommendation of "Reduce" from the ten research firms that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and eight have issued a hold recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $9.6222.

Several equities research analysts have weighed in on YMAB shares. Brookline Capital Management lowered shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Wedbush lowered shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and set a $8.60 price objective on the stock. in a research report on Tuesday, August 5th. Jones Trading cut shares of Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Oppenheimer downgraded Y-mAbs Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Tuesday, August 5th. Finally, Morgan Stanley set a $8.60 price target on Y-mAbs Therapeutics in a research note on Tuesday, August 5th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Brooklyn Investment Group raised its stake in shares of Y-mAbs Therapeutics by 4,563.8% in the first quarter. Brooklyn Investment Group now owns 5,923 shares of the company's stock valued at $26,000 after buying an additional 5,796 shares during the period. CWM LLC raised its position in Y-mAbs Therapeutics by 203.0% during the second quarter. CWM LLC now owns 7,121 shares of the company's stock valued at $32,000 after purchasing an additional 4,771 shares in the last quarter. Raymond James Financial Inc. purchased a new stake in Y-mAbs Therapeutics during the second quarter valued at about $35,000. Los Angeles Capital Management LLC bought a new position in shares of Y-mAbs Therapeutics during the second quarter valued at about $46,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in Y-mAbs Therapeutics in the first quarter worth about $49,000. Hedge funds and other institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Trading Up 0.1%

YMAB stock opened at $8.60 on Wednesday. The firm has a market cap of $390.78 million, a P/E ratio of -17.20 and a beta of 0.54. Y-mAbs Therapeutics has a 1-year low of $3.55 and a 1-year high of $16.11. The business's 50 day moving average is $7.02 and its 200-day moving average is $5.42.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its earnings results on Friday, August 8th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.20. Y-mAbs Therapeutics had a negative return on equity of 24.60% and a negative net margin of 26.03%.The business had revenue of $19.52 million for the quarter, compared to the consensus estimate of $18.40 million. Sell-side analysts forecast that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.